Cullinan Therapeutics, Inc. filings document formal disclosures for a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Recent Form 8-K reports furnish operating results and financial-condition updates, Regulation FD materials, and clinical disclosures tied to programs including CLN-978, CLN-049 and zipalertinib.
The filing record also covers corporate and governance matters, including definitive proxy disclosures on executive and director compensation, equity awards and shareholder voting matters. Material-event filings document portfolio and contractual actions, including the termination of an exclusive patent license related to CLN-617 through Cullinan Amber Corp.
Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson reported an exercise-and-sell transaction in company stock. She sold a total of 8,000 shares of Common Stock in open-market transactions at weighted average prices of $14.60 and $15.58, with actual trade prices ranging from $14.24 to $15.60. These sales were executed pursuant to a pre-established Rule 10b5-1 trading plan dated August 7, 2025. On the same day, she exercised stock options for 4,000 shares of Common Stock at an exercise price of $4.30 per share, converting a derivative position into additional common shares while using part of her holdings for liquidity.
CGEM-related insider reported proposed sales. The filing lists multiple proposed and completed dispositions of Common stock, including 10b5-1 sales on 03/05/2026 for 8,000 shares at $125,453.60 and an exercise of stock options to sell 4,000 shares on 05/05/2026. The excerpt also shows 4,000 RSUs dated 02/22/2024.
Cullinan Therapeutics, Inc. has registered securities on a Form S-3 shelf and may sell up to $200,000,000 of its common stock through an at-the-market sales agreement with TD Securities (USA) LLC (TD Cowen). Sales may occur "from time to time" at market-determined prices under the sales agreement.
The prospectus covers multiple security types but the accompanying base prospectus and sales agreement specifically permit the company to offer common stock with proceeds to be used for general corporate purposes, including R&D, clinical trials, in-licensing and potential acquisitions.
Cullinan Therapeutics, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 16, 2026. The agenda includes electing two Class III directors, Nadim Ahmed and Stephen Webster, to serve until the 2029 annual meeting, ratifying KPMG LLP as independent auditor for 2026, and approving an advisory vote on named executive officer compensation.
The record date is April 20, 2026, with 61,451,380 common shares entitled to vote. The proxy details virtual-only access, board and committee structure, director pay, and executive pay, including 2025 total compensation of $5,100,006 for CEO Nadim Ahmed, $2,221,578 for CMO Jeffrey Jones, and $2,078,837 for CFO Mary Kay Fenton.
Cullinan Therapeutics Inc ownership update: The Vanguard Group reports beneficial ownership of 0 shares of Common Stock as of the amendment filing, following an internal realignment. The filing states on January 12, 2026 certain Vanguard subsidiaries will report ownership separately in reliance on SEC Release No. 34-39538.
Cullinan Therapeutics, Inc. files its annual report describing an expanded pipeline in autoimmune disease and oncology and its collaboration strategy. The company highlights CLN-978, a CD19xCD3 T cell engager in Phase 1 trials for lupus, rheumatoid arthritis and Sjögren’s disease, and velinotamig, a BCMAxCD3 engager licensed from Genrix for plasma cell–driven autoimmune conditions.
In oncology, CLN-049, a FLT3xCD3 T cell engager for AML and MDS, has Phase 1 data showing complete response plus partial hematologic recovery rates up to 31% at certain doses and has Fast Track designation. Zipalertinib, partnered with Taiho, has pivotal REZILIENT1 data in EGFR exon 20 insertion NSCLC, supporting a completed rolling NDA submission for accelerated approval and a global Phase 3 first-line trial now fully enrolled. The company also outlines substantial potential milestone and profit‑share economics from Taiho and details key licensing agreements and an IP estate with patents extending into the 2040s.
Cullinan Therapeutics reported a full-year 2025 net loss attributable to the company of $219.9 million, compared with $167.4 million in 2024, driven mainly by higher research and development spending. Cash, equivalents, investments and interest receivable totaled $439.0 million as of December 31, 2025, which the company expects will fund operations into 2029.
The company highlighted multiple 2026 milestones, including initial clinical data for CLN-978 in systemic lupus erythematosus and rheumatoid arthritis in Q2 2026 and repeat dosing data in Q3 2026. Partner Taiho completed a rolling NDA submission and enrollment of the REZILIENT3 frontline study for zipalertinib, while Cullinan plans to advance CLN-049 toward registrational development in acute myeloid leukemia.
Cullinan Therapeutics, Inc. Chief Scientific Officer Jennifer Michaelson reported option exercises and a share sale. On the same day, she exercised stock options for 4,000 shares of common stock at $4.30 per share through a derivative exercise, and then sold 8,000 common shares in the open market at a weighted average price of $15.68 per share, with individual trades ranging from $15.38 to $16.31. The sale was made under a pre-established Rule 10b5-1 trading plan dated August 7, 2025. Following these transactions, she directly held 170,844 shares of common stock and 120,987 shares underlying stock options.
Jennifer Michaelson reported Form 144 proposed sales of Common shares. The filing lists an exercise of stock options for 4,000 shares dated 03/05/2026 and 4,000 Restricted Stock Units dated 12/11/2024.
The excerpt also itemizes multiple 10b5-1 sale transactions by Ms. Michaelson during late 2025 and early 2026, including 8,000 shares on 02/20/2026, 4,000 shares on 01/22/2026, and smaller lots on various dates with dollar amounts shown.